FDA Clearance Tracker · P020014-S017
CONCEPTUS ESSURE SYSTEM FOR PERMANENT BIRTH CONTROL
Last checked: Nov 20, 2026Latest source record: Feb 24, 2012 (this decision)Source: openFDAMethods & limitations
Decided
Feb 24, 2012
Approved
Time to decision
1,421 days
Received Apr 4, 2008. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P020014-S017
- Device name
- CONCEPTUS ESSURE SYSTEM FOR PERMANENT BIRTH CONTROL
- Applicant
- Bayer Pharma AG
- Applicant location
- Berlin
- Received
- Apr 4, 2008
- Decided
- Feb 24, 2012
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P020014
Device type
- Device class
- Class III
- Regulation
- 21 CFR 884.5380
- Specialty
- Obstetrics & Gynecology
FDA's approval statement
As written in FDA's record.
APPROVAL TO MODIFY THE EXISTING RF ENERGY WARNING TO ADD AN ESSURE/ NOVASURE WARNING. ADDITIONALLY, THE PMA SUPPLEMENT INCLUDES APPROVAL OF A POST-APPROVAL STUDY.
Source documents
Other decisions for Bayer Pharma AG
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.